State sequence analysis of daily methadone dispensing trajectories among individuals at United States opioid treatment programs before and following COVID‐19 onset.
Saved in:
| Title: | State sequence analysis of daily methadone dispensing trajectories among individuals at United States opioid treatment programs before and following COVID‐19 onset. |
|---|---|
| Authors: | Bórquez, Ignacio, Williams, Arthur R., Hu, Mei‐Chen, Scott, Marc, Stewart, Maureen T., Harpel, Lexa, Aydinoglo, Nicole, Cerdá, Magdalena, Rotrosen, John, Nunes, Edward V., Krawczyk, Noa |
| Source: | Addiction. Jun2025, Vol. 120 Issue 6, p1207-1222. 16p. |
| Subjects: | Substance abuse, Methadone hydrochloride, Research funding, Health policy, Retrospective studies, Descriptive statistics, Longitudinal method, Opioid analgesics, Medical records, Acquisition of data, Housing, Comparative studies, COVID-19 pandemic, Sequence analysis, COVID-19 |
| Geographic Terms: | United States |
| Abstract: | Background and aims: US regulatory changes allowed for additional methadone take‐home doses following COVID‐19 onset. How dispensing practices changed and which factors drove variation remains unexplored. We determined daily methadone dispensing trajectories over six months before and after regulatory changes due to COVID‐19 using state sequence analysis and explored correlates. Design: Retrospective chart review of electronic health records. Settings Nine opioid treatment programs (OTPs) across nine US states. Participants: Adults initiating treatment in 2019 (n = 328) vs. initiating 1 month after the COVID‐19 regulatory changes of March 2020 (n = 376). Measurements Type of daily methadone medication encounter (in‐clinic, weekend/holiday take‐home, take‐home, missed dose, discontinued) based on OTP clinic; cohort (pre vs. post‐COVID‐19); and patient substance use, clinical and sociodemographic characteristics. Findings Following COVID‐19 regulatory changes, allotted methadone take‐home doses increased from 3.5% to 13.8% of total person‐days in treatment within the first 6 months in care. Clinic site accounted for the greatest variation in methadone dispensing (6.2% and 9.5% of the variation of discrepancy between sequences pre‐ and post‐COVID‐19, respectively). People who co‐use methamphetamine had a greater increase in take‐homes than people who did not use methamphetamine (from 3.7% pre‐pandemic to 21.2% post‐pandemic vs. 3.5% to 12.5%) and higher discontinuation (average 3.6 vs. 4.7 months among people who did not use methamphetamine pre‐COVID‐19; average 3.3 vs. 4.6 months post‐COVID‐19). In the post‐COVID‐19 cohort, females had a higher proportion of missed doses (17.2% vs. 11.9%) than males. People experiencing houselessness had a higher proportion of missed doses (19% vs. 12.3%) and shorter stays (average 3.5 vs. 4.5 months) when compared with those with stable housing. Conclusion: Daily methadone dispensing trajectories in the US both before and following COVID‐19 regulatory changes appeared to depend more on the opioid treatment programs' practices than individual patient characteristics or response to treatment. [ABSTRACT FROM AUTHOR] |
| Copyright of Addiction is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
